Ezetimibe is a nonstatin low-density lipoprotein cholesterol-lowering small molecule drug. Ezetimibe is the only currently FDA-approved approved member of the of intestinal cholesterol reuptake ...
Five years of statin therapy lowers low-density lipoprotein (LDL) cholesterol substantially and, over a 5-year period, results in reductions in the incidence of cardiovascular events. The Simvastatin ...
- NILEMDO® (bempedoic acid) is the first oral, once-daily treatment approved in almost two decades to lower low-density lipoprotein cholesterol (LDL-C) for indicated patients - - Bempedoic acid and ...
The 2019 guideline for the management of dyslipidemias published by the European Society of Cardiology (ESC) in partnership with the European Atherosclerosis Society (EAS), recommended a further ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results